These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24629217)

  • 1. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
    Alistar SS; Grant PM; Bendavid E
    BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.
    Alistar SS; Owens DK; Brandeau ML
    PLoS One; 2014; 9(1):e86584. PubMed ID: 24489747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
    Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
    AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.
    Pretorius C; Stover J; Bollinger L; Bacaër N; Williams B
    PLoS One; 2010 Nov; 5(11):e13646. PubMed ID: 21079767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of antiretroviral treatment vs. circumcision for HIV prevention.
    Bärnighausen T; Bloom DE; Humair S
    Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21271-6. PubMed ID: 23223563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.
    Shen M; Xiao Y; Rong L; Meyers LA; Bellan SE
    BMC Med; 2018 Apr; 16(1):58. PubMed ID: 29688862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
    Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
    Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
    Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
    Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
    Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
    BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
    Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
    J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.